Published in Clin Cancer Res on September 15, 2008
Genetic correction of PSA values using sequence variants associated with PSA levels. Sci Transl Med (2010) 2.83
Polygenic susceptibility to prostate and breast cancer: implications for personalised screening. Br J Cancer (2011) 2.28
Sequence variants at 22q13 are associated with prostate cancer risk. Cancer Res (2009) 2.27
Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients. Prostate (2009) 1.95
Fine mapping association study and functional analysis implicate a SNP in MSMB at 10q11 as a causal variant for prostate cancer risk. Hum Mol Genet (2009) 1.90
Two independent prostate cancer risk-associated Loci at 11q13. Cancer Epidemiol Biomarkers Prev (2009) 1.78
The complexity of prostate cancer: genomic alterations and heterogeneity. Nat Rev Urol (2012) 1.59
The genetic epidemiology of prostate cancer and its clinical implications. Nat Rev Urol (2013) 1.39
Association of reported prostate cancer risk alleles with PSA levels among men without a diagnosis of prostate cancer. Prostate (2009) 1.33
Evaluation of 8q24 and 17q risk loci and prostate cancer mortality. Clin Cancer Res (2009) 1.27
Early onset prostate cancer has a significant genetic component. Prostate (2011) 1.26
Established prostate cancer susceptibility variants are not associated with disease outcome. Cancer Epidemiol Biomarkers Prev (2009) 1.24
Association of prostate cancer risk Loci with disease aggressiveness and prostate cancer-specific mortality. Cancer Prev Res (Phila) (2011) 1.17
Genetic polymorphism and prostate cancer aggressiveness: a case-only study of 1,536 GWAS and candidate SNPs in African-Americans and European-Americans. Prostate (2012) 1.14
Prostate cancer genomics: can we distinguish between indolent and fatal disease using genetic markers? Genome Med (2010) 1.09
Genetic prostate cancer risk assessment: common variants in 9 genomic regions are associated with cumulative risk. J Urol (2010) 1.08
Prostate cancer susceptibility variants confer increased risk of disease progression. Cancer Epidemiol Biomarkers Prev (2010) 1.06
Association of KLK3 (PSA) genetic variants with prostate cancer risk and PSA levels. Carcinogenesis (2011) 1.04
Risk factors for prostate cancer. Nat Clin Pract Urol (2009) 1.03
Prostate cancer predisposition loci and risk of metastatic disease and prostate cancer recurrence. Clin Cancer Res (2011) 1.01
A comprehensive resequence analysis of the KLK15-KLK3-KLK2 locus on chromosome 19q13.33. Hum Genet (2009) 1.01
Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis. Genet Med (2015) 1.01
Associations of prostate cancer risk variants with disease aggressiveness: results of the NCI-SPORE Genetics Working Group analysis of 18,343 cases. Hum Genet (2015) 0.95
The genetics of cancer risk. Cancer J (2011) 0.85
The prostate cancer susceptibility variant rs2735839 near KLK3 gene is associated with aggressive prostate cancer and can stratify gleason score 7 patients. Clin Cancer Res (2014) 0.84
Kallikrein 3 and vitamin D receptor polymorphisms: potentials environmental risk factors for prostate cancer. Diagn Pathol (2014) 0.83
Polymorphisms influencing prostate-specific antigen concentration may bias genome-wide association studies on prostate cancer. Cancer Epidemiol Biomarkers Prev (2014) 0.79
Fine-mapping and family-based association analyses of prostate cancer risk variants at Xp11. Cancer Epidemiol Biomarkers Prev (2009) 0.79
Fine-mapping of prostate cancer aggressiveness loci on chromosome 7q22-35. Prostate (2010) 0.78
Incorporating Known Genetic Variants Does Not Improve the Accuracy of PSA Testing to Identify High Risk Prostate Cancer on Biopsy. PLoS One (2015) 0.75
The rs10993994 in the proximal MSMB promoter region is a functional polymorphism in Asian Indian subjects. Springerplus (2015) 0.75
A new multipoint method for genome-wide association studies by imputation of genotypes. Nat Genet (2007) 52.68
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet (2007) 21.18
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet (2007) 19.18
Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet (2008) 17.65
Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet (2008) 15.43
Cumulative association of five genetic variants with prostate cancer. N Engl J Med (2008) 15.34
Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet (2007) 14.37
A common variant associated with prostate cancer in European and African populations. Nat Genet (2006) 13.47
Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet (2007) 12.65
The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol (2005) 12.31
Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci U S A (2006) 10.32
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet (2008) 6.10
Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst (2007) 4.85
Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. J Natl Cancer Inst (2007) 4.24
The complex genetic epidemiology of prostate cancer. Hum Mol Genet (2004) 3.21
A common 8q24 variant in prostate and breast cancer from a large nested case-control study. Cancer Res (2007) 3.08
Two common chromosome 8q24 variants are associated with increased risk for prostate cancer. Cancer Res (2007) 2.56
Confirmation study of prostate cancer risk variants at 8q24 in African Americans identifies a novel risk locus. Genome Res (2007) 2.53
Confirmation of a positive association between prostate cancer risk and a locus at chromosome 8q24. Cancer Epidemiol Biomarkers Prev (2007) 2.11
The common variant rs1447295 on chromosome 8q24 and prostate cancer risk: results from an Australian population-based case-control study. Cancer Epidemiol Biomarkers Prev (2007) 1.95
8q24 and prostate cancer: association with advanced disease and meta-analysis. Eur J Hum Genet (2008) 1.72
Natural history of pathologically organ-confined (pT2), Gleason score 6 or less, prostate cancer after radical prostatectomy. Urology (2008) 1.27
Association between sequence variants at 17q12 and 17q24.3 and prostate cancer risk in European and African Americans. Prostate (2008) 1.24
Staging prostate cancer. Microsc Res Tech (2000) 1.20
Pathologic assessment of the surgical specimen. Urol Clin North Am (2001) 1.12
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet (2007) 19.18
Cumulative association of five genetic variants with prostate cancer. N Engl J Med (2008) 15.34
A common variant associated with prostate cancer in European and African populations. Nat Genet (2006) 13.47
Inflammation in prostate carcinogenesis. Nat Rev Cancer (2007) 9.08
Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA (2005) 8.72
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet (2008) 7.14
Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res (2009) 7.11
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med (2014) 6.89
The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature (2011) 6.71
Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med (2009) 6.61
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet (2008) 6.10
Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst (2006) 6.02
NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw (2010) 5.98
Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study. Circulation (2007) 5.87
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet (2013) 5.58
Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med (2012) 5.49
Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol (2011) 5.27
Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA (2008) 5.25
Glucose levels and risk of dementia. N Engl J Med (2013) 4.95
Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst (2007) 4.85
GWAS of 126,559 individuals identifies genetic variants associated with educational attainment. Science (2013) 4.71
Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol (2003) 4.66
Pathological correlates of dementia in a longitudinal, population-based sample of aging. Ann Neurol (2007) 4.47
Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. J Natl Cancer Inst (2007) 4.24
African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them? J Clin Oncol (2013) 4.20
Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol (2010) 4.17
Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet (2010) 3.83
Identification of a new prostate cancer susceptibility locus on chromosome 8q24. Nat Genet (2009) 3.76
Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J Clin Invest (2013) 3.47
Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol (2011) 3.36
Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA (2006) 3.32
Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res (2004) 3.29
Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA (2007) 3.25
Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture. Nat Genet (2013) 3.25
An evaluation of the decreasing incidence of positive surgical margins in a large retropubic prostatectomy series. J Urol (2004) 3.21
Hepatic steatosis and subclinical cardiovascular disease in a cohort enriched for type 2 diabetes: the Diabetes Heart Study. Am J Gastroenterol (2008) 3.16
Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat Genet (2008) 3.14